You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tislelizumab

Showing 1 - 25 of 387
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Intrahepatic Cholangiocarcinoma, Gallbladder Cancer Trial (HAIC, Surufatinib, Tislelizumab)

Not yet recruiting
  • Carcinoma
  • +7 more
  • (no location specified)
Nov 12, 2023

Cervical Cancer Trial (Nimotuzumab?Tislelizumab)

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
Sep 9, 2023

Tislelizumab Combined With Chemotherapy in First-line Treatment

Active, not recruiting
  • Tislelizumab
  • +3 more
  • Tislelizumab
  • Beijing, China
    Cancer Institute and Hospital, Chinese Academy of Medical Scienc
Sep 6, 2023

Tislelizumab, Bevacizumab, Oxaliplatin Trial in Beijing (Tislelizumab+Bevacizumab+Oxaliplatin+Capecitabine)

Recruiting
  • Tislelizumab
  • +7 more
  • Beijing, China
    Lin Yang
Jul 21, 2023

Resectable Hepatocellular Carcinoma Trial (Tislelizumab, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • Tislelizumab
  • Tislelizumab, Lenvatinib
  • (no location specified)
Mar 29, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC)

Recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Jul 12, 2023

Extensive Stage Small Cell Lung Cancer Trial in Hangzhou (Tislelizumab, Anlotinib)

Recruiting
  • Extensive Stage Small Cell Lung Cancer
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Jun 6, 2023

Solid Tumor, Adult Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)

Recruiting
  • Solid Tumor, Adult
  • Tislelizumab
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 13, 2023

Advanced Colorectal Cancer Trial in Hangzhou (Cetuximab Dabrafenib Tislelizumab)

Not yet recruiting
  • Advanced Colorectal Cancer
  • Cetuximab Dabrafenib Tislelizumab
  • Hangzhou, Zhejing, China
    Zhejiang Cancer Institute & Hospital
Jul 19, 2023

NSCLC Trial (Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Tislelizumab IV
  • +2 more
  • (no location specified)
Oct 25, 2023

Hepatocellular Carcinoma Trial in Beijing (Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib Plus Tislelizumab
  • Transarterial Chemoembolization(TACE)
  • Beijing, Beijing, China
    Nan Zhang
Apr 22, 2023

Colonic Tumors, Neoadjuvant Therapy, Immune Checkpoint Inhibitors Trial in Nanning (Tislelizumab, Oxaliplatin, Capecitabine)

Recruiting
  • Colonic Neoplasms
  • +2 more
  • Tislelizumab
  • +3 more
  • Nanning, Guangxi, China
    The First Affiliated Hospital of Guangxi Medical University
Nov 9, 2023

Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer Trial in Tianjin

Recruiting
  • Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Nov 16, 2022

Hepatocellular Carcinoma Trial (Cryoablation, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Cryoablation
  • +2 more
  • (no location specified)
May 31, 2023

MSI-H Colorectal Cancer, Tislelizumab, Oxaliplatin Trial (Tislelizumab)

Not yet recruiting
  • MSI-H Colorectal Cancer
  • +3 more
  • Tislelizumab
  • (no location specified)
Apr 23, 2023

NSCLC Trial in Zhengzhou (L-TIL, Tislelizumab, Docetaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • L-TIL, Tislelizumab, Docetaxel
  • Zhengzhou, Henan, China
    No.127 Dongming Road
May 17, 2023

Cervical Cancer Recurrent Trial in Beijing (RC48 + Tislelizumab)

Recruiting
  • Cervical Cancer Recurrent
  • RC48 + Tislelizumab
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 25, 2023

Lung Adenocarcinoma Trial in Shijiazhuang (Tislelizumab,Platinum)

Recruiting
  • Lung Adenocarcinoma
  • Shijiazhuang, Hebei, China
    The Fourth Hospital of Hebei Medical University (Hebei Tumor Hos
Sep 24, 2023

Advanced Biliary Tract Cancer Trial (H101, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Advanced Biliary Tract Cancer
  • (no location specified)
Apr 11, 2023

Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Oct 14, 2022

Glioblastoma Trial (Tislelizumab and Bevacizumab)

Not yet recruiting
  • Glioblastoma
  • Tislelizumab and Bevacizumab
  • (no location specified)
Apr 12, 2023

Hodgkin Lymphoma Trial (Tislelizumab, AVD, Radiotherapy)

Not yet recruiting
  • Hodgkin Lymphoma
  • Tislelizumab, AVD, Radiotherapy
  • (no location specified)
Nov 15, 2022

Locally Advanced Rectal Cancer Trial in Beijing (Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor), Long-course

Recruiting
  • Locally Advanced Rectal Cancer
  • Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)
  • Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Apr 25, 2023

Gastric Cancer Metastatic to Liver Trial in Shanghai (Cryoablation, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Gastric Cancer Metastatic to Liver
  • Cryoablation
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 6, 2023

Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor Trial in Nanning (Adjuvant tislelizumab plus lenvatinib,

Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Adjuvant tislelizumab plus lenvatinib
  • Adjuvant tislelizumab
  • Nanning, China
    Jian-Hong Zhong
Jun 11, 2023